Aura Biosciences, Inc. presented positive clinical efficacy updates of belzupacap sarotalocan (bel-sar) for early stage choroidal melanoma (CM) at the AAO 2023 Annual Meeting. The company also received FDA agreement under a Special Protocol Assessment (SPA) for the design and planned analysis of CoMpass Phase 3 clinical trial of bel-sar.